NCT02254109已完成1 期
A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Number of subjects with abnormal findings in physical examination
研究概览
简要总结
Study to evaluate safety, tolerability, and pharmacokinetics of BEA 2180 BR in Japanese healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Japanese men:
- •According to the results of a complete medical history, the physical examination, vital signs (blood pressure and pulse rate), 12-lead ECG, clinical laboratory tests
- •Age ≥20 and ≤35 years
- •Body mass index (BMI) ≥18.5 and ≤25 kg/m2
- •Subjects must be able to inhale medication in a competent manner from the Respimat®
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP)
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity including allergy to drug or its excipients
- •Intake of drugs with a long half-life (>24 hours) within one month or less than 10 half-lives of the respective drug before drug administration or during the trial
- •Use of prescription or non-prescription drugs within 10 days before drug Administration or during the trial. However, over-the-counter (OTC) drugs for external application (such as lubricant eye drops for contact lens, insect bite reliever) shall be allowed
- •Participation in another trial with an investigational drug within four months before drug administration or during the trial
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
- •Inability to refrain from smoking during the trial
- •Alcohol abuse (≥60 g/day: corresponds to ca. 3 large bottles of beer, 3 gous (ca. 540 cc) of Japanese sake, 6 shots of whisky, 6 glasses of wine or 6 glasses of Japanese shochu, distilled alcoholic beverage)
- •Blood donation (≥100 mL within four weeks before drug administration or during the trial)
- •Excessive physical activities (within one week before drug administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •Exclusion criteria specific for this study:
- •Occupational (professional) exposure to antimuscarinic substances (e.g., physician, nurse, pharmacist etc.; volunteers working for medical institutions, research institutions or herb gardens)
- •History of glaucoma, urination difficulty (due to prostatic hyperplasia etc.)
研究组 & 干预措施
BEA 2180 BR - rising dose
Experimental
干预措施: BEA 2180 BR - rising dose (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of subjects with abnormal findings in physical examination
时间窗: up to 28 days after last dose administration
Number of subjects with clinically significant changes in vital signs
时间窗: up to 28 days after last dose administration
Blood pressure and pulse rate
Number of subjects with clinically significant changes in 12-lead electrocardiogram (ECG)
时间窗: up to 28 days after last dose administration
Number of subjects with adverse events
时间窗: up to 28 days after last dose administration
Number of subjects with abnormal changes in laboratory parameters
时间窗: up to 28 days after last dose administration
Assessment of tolerability by the investigator on a 4-point scale
时间窗: 28 days after last dose administration
次要结局
- Cmax (maximum measured concentration of the analyte in plasma)(up to 648:00 hours)
- tmax (time from dosing to maximum measured concentration of the analyte in plasma)(up to 648:00 hours)
- AUCτ (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ)(up to 648:00 hours)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz)(up to 648:00 hours)
- feτ (fraction of analyte eliminated in urine over a uniform dosing interval τ)(up to 648:00 hours)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(up to 648:00 hours)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)(up to 648:00 hours)
- Aeτ (amount of analyte that is eliminated in urine over a uniform dosing interval τ)(up to 648:00 hours)
- λz,ss (terminal rate constant in plasma at steady state)(up to 648:00 hours)
- Accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax)(up to 648:00 hours)
- Cmin,ss (minimum concentration of the analyte in plasma at steady state)(up to 648:00 hours)
- Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)(up to 648:00 hours)
- t1/2,ss (terminal half-life of the analyte in plasma at steady state)(up to 648:00 hours)
- MRTih,ss (mean residence time of the analyte in the body at steady state after inhalation administration)(up to 648:00 hours)
- CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration)(up to 648:00 hours)
- Accumulation ratio of the analyte in plasma based on AUC (RA,AUC)(up to 648:00 hours)
- Accumulation ratio of the analyte in plasma based on Ae (RA,Ae)(up to 648:00 hours)
研究者
相似试验
已完成
1 期
Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male VolunteersHealthyNCT02172105Boehringer Ingelheim36
已完成
1 期
Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsParkinson DiseaseNCT01520987Bial - Portela C S.A.105
已完成
1 期
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese ParticipantsThrombosisNCT03224260Bristol-Myers Squibb33
已完成
1 期
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male VolunteersHealthyNCT02214901Boehringer Ingelheim91
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male VolunteersHealthyNCT02273401Boehringer Ingelheim96